company background image
300347 logo

Hangzhou Tigermed Consulting XSEC:300347 Stock Report

Last Price

CN¥59.17

Market Cap

CN¥47.4b

7D

-4.4%

1Y

8.9%

Updated

23 Dec, 2024

Data

Company Financials +

Hangzhou Tigermed Consulting Co., Ltd

XSEC:300347 Stock Report

Market Cap: CN¥47.4b

300347 Stock Overview

Provides contract research organization services in the People’s Republic of China and internationally. More details

300347 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance1/6
Financial Health5/6
Dividends5/6

Rewards

Trading at 35.2% below our estimate of its fair value

Earnings are forecast to grow 33.99% per year

Pays a reliable dividend of 0.96%

Risk Analysis

Large one-off items impacting financial results

Profit margins (14.1%) are lower than last year (31.1%)


My Notes

Capture your thoughts, links and company narrative

Hangzhou Tigermed Consulting Co., Ltd Competitors

Pharmaron Beijing

SZSE:300759

CN¥44.4b

WuXi AppTec

SHSE:603259

CN¥160.9b

HitGen

SHSE:688222

CN¥5.2b

Shanghai Haoyuan Chemexpress

SHSE:688131

CN¥7.7b

Price History & Performance

Summary of share price highs, lows and changes for Hangzhou Tigermed Consulting
Historical stock prices
Current Share PriceCN¥59.17
52 Week HighCN¥82.79
52 Week LowCN¥36.12
Beta0.86
1 Month Change-3.52%
3 Month Change15.14%
1 Year Change8.95%
3 Year Change-50.94%
5 Year Change-3.79%
Change since IPO214.40%

Recent News & Updates

Recent updates

Shareholder Returns

300347CN Life SciencesCN Market
7D-4.4%-1.5%-1.2%
1Y8.9%-18.1%11.8%

Return vs Industry: 300347 exceeded the CN Life Sciences industry which returned -18.1% over the past year.

Return vs Market: 300347 underperformed the CN Market which returned 11.8% over the past year.

Price Volatility

Is 300347's price volatile compared to industry and market?
300347 volatility
300347 Average Weekly Movement10.5%
Life Sciences Industry Average Movement10.1%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.7%

Stable Share Price: 300347 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 300347's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20049,348Xiaochun Caowww.tigermedgrp.com

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.

Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary

How do Hangzhou Tigermed Consulting's earnings and revenue compare to its market cap?
300347 fundamental statistics
Market capCN¥47.40b
Earnings (TTM)CN¥958.67m
Revenue (TTM)CN¥6.80b

53.2x

P/E Ratio

7.5x

P/S Ratio

Is 300347 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300347 income statement (TTM)
RevenueCN¥6.80b
Cost of RevenueCN¥4.27b
Gross ProfitCN¥2.54b
Other ExpensesCN¥1.58b
EarningsCN¥958.67m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.11
Gross Margin37.29%
Net Profit Margin14.10%
Debt/Equity Ratio15.2%

How did 300347 perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

51%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:37
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Tigermed Consulting Co., Ltd is covered by 39 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang LuoBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Bo LiBofA Global Research